Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487188 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT00487188 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 47 participants.
The verdict
NCT00487188, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
To assess the efficacy of enfuvirtide (Fuzeon) added to HAART compared to treatment with HAART alone in achieving and maintaining viral load suppression.
Interventions
- DRUG Enfuvirtide
- DRUG Highly active antiretroviral treatment (HAART)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00487188
The ClinicalTrials.gov registry entry for NCT00487188 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enfuvirtide is the first listed.
NCT00487188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00487188 about?
NCT00487188 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience". To assess the efficacy of enfuvirtide (Fuzeon) added to HAART compared to treatment with HAART alone in achieving and maintaining viral load suppression.
What is the current status of trial NCT00487188?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2005-11. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00487188?
The interventions under investigation include: Enfuvirtide (DRUG), Highly active antiretroviral treatment (HAART) (DRUG).
Who is sponsoring clinical trial NCT00487188?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.